Home Stock Market Receiving COVIDs poses a much rarer risk of blood clots than vaccines,...

Receiving COVIDs poses a much rarer risk of blood clots than vaccines, Oxford research shows


A new study from researchers at Oxford University has found that people infected with COVID-19 have a much higher risk of forming blood clots than those receiving COVID-19 vaccine, reinforcing. vaccine use cases.

Research, published in pre-print on Thursday, meaning it has yet to be peer-reviewed, has found that the risk of cerebral vein thrombosis, or CVT, after COVID-19 infection is approximately higher than normal. 100 times and several times higher than after getting coronavirus vaccine or after getting the flu.

The researchers, led by Professor Paul Harrison and Dr. Maxime Taquet from the Department of Psychiatry at Oxford University and the NIHR Oxford Medical Biomedical Research Center, studied the number of CVT cases diagnosed in two weeks after someone tests positive for COVID-19, or two weeks. after the first dose of vaccine. They then compared those numbers with the CVT incidents diagnosed when someone got sick with the flu and how common it is in the general population.

Researchers found that the incidence of CVT was more common after COVID-19 than any of the comparison groups and about 8 to 10 times higher in people who had received the COVID-19 vaccine. , namely two mRNA vaccines by Pfizer Inc.
PFE,
+ 1.16%

and German partner BioNTech SE
BNTX,
+ 6.12%
,
and by Moderna Inc.
MRNA,
-0.10%
,
or adenovirus vector-based vaccine developed by AstraZeneca PLC
AZN,
+ 1.99%

AZN,
-0.54%

and Oxford University. All 30% of detected CVT cases occur in people under the age of 30 who are infected with COVID.

The problem is as follows:



The authors wrote that the data must be interpreted with caution as it is still being compiled.

“We have reached two important conclusions,” said Harrison. “First, COVID-19 significantly increases the risk of CVT, adding to the list of clotting problems this infection causes. Second, the COVID-19 risk is higher than we see with current vaccines, even for those under 30 years of age; something to keep in mind when weighing the risks and benefits of vaccination ”.

Research comes amid the increasingly closely monitored AstraZeneca vaccine and its link to rare but severe blood clots, and after regulatory agencies of the United States. suggest suspending use of vaccines developed by Johnson & Johnson, also a vaccine based on adenovirus virus vectors, after Six women were hospitalized for a rare type of blood clot. This is also very small compared to 6.8 million people who have been vaccinated.

The European Pharmaceutical Authority said recently it found a linbetween the coagulation cases and the AstraZeneca vaccine, although it is emphasized that this problem is still very rare. On Wednesday, Denmark became the first country to stop using AstraZeneca jets completely.

Read more: Rare coagulation problem dominated COVID news as Denmark dropped AstraZeneca vaccine

Center for Disease Control and Prevention Advisory Committee held an emergency meeting on Wednesday to discuss J&J vaccine data and chose to remain paused to further explore the issue.

See: Johnson & Johnson vaccine interruptions: What you need to know if you’ve already had or scheduled an injection

In the case of the J&J vaccine, blood clots occurred due to cerebral sinus thrombosis combined with thrombocytopenia, a condition that causes low platelet counts in the blood.

“Although a cause and effect relationship has not been fully established between these very rare events and our vaccines, we have found that these events may represent a potentially significant risk. on Janssen vaccines, ”said Dr. Aran Maree, medical director of J & J’s drug business, during the meeting.

The commission will re-convene on a scheduled date to be revealed on Friday.

Many health experts continue to believe that the benefits of the vaccine far outweigh the risk of COVID-19 infection, which can come with a host of serious side effects.

“The COVID-19 vaccine is effective and a key tool for pandemic control,” said CDC spokesman Kristin Nordlund. “All available vaccines have been shown to be effective in preventing serious illness, hospitalization and death.”

The CDC commented on the small number of breakthrough COVID-19 infections that occurred even in fully vaccinated people. So far, the agency has counted only 5,800 breakthrough infections out of about 124 million Americans who received the first dose. These cases are thought to be vaccines that are not 100% effective in preventing infection and a reminder that people need to continue to adhere to safety measures after vaccination, i.e. frequent washing. hands, keep away from society and wear a mask in public.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments